Loading clinical trials...

A Study of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal Impairment | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGPHASE1

A Study of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal Impairment

A Phase I Clinical Study to Evaluate the Safety, Tolerability, PK and PD of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal Impairment

NCT07445906•Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.

View on ClinicalTrials.gov

Summary

This is a Phase I trial designed to evaluate the impact of renal impairment on the efficacy and safety of the drug by comparing pharmacokinetic (PK) parameters and pharmacodynamic (PD) markers after a single subcutaneous injection of RG002C0106 between trial participants with normal renal function and those with mild to moderate renal impairment.

Eligibility

Age

18 - 60 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Have been fully informed about the study, volunteered to participate, and provided written informed consent.
•2. Male or female participants aged 18-60 years (inclusive) at screening.
•3. Body mass index (BMI) of 19.0-32.0 kg/m² (inclusive) at screening; body weight ≥ 50 kg for male participants and ≥ 45 kg for female participants.
•4. Absolute estimated glomerular filtration rate (eGFR), calculated using the CKD-EPI 2021 equation during the screening period, falls into the corresponding group as follows:
•Normal renal function: absolute eGFR ≥ 90 mL/min; Mild renal impairment: 60 mL/min ≤ absolute eGFR \< 90 mL/min; Moderate renal impairment: 30 mL/min ≤ absolute eGFR \< 60 mL/min.
•5. Female participants of childbearing potential must have a negative serum pregnancy test during the screening period. Highly effective contraception must be used from signing the informed consent form until 6 months after the last dose of the study drug, by the participant and their partner of childbearing potential.

Exclusion Criteria

•1. At screening, chest radiography demonstrates clinically significant abnormalities.
•2. Any of the following abnormal laboratory test results at screening:
•Total bilirubin \> 1.5 × upper limit of normal (ULN); ALT or AST \> 2 × ULN; International normalized ratio (INR) \> 2 or any clinically significant abnormality; QTcF ≥ 450 ms in males or QTcF ≥ 470 ms in females (QTc interval must be heart rate-corrected using the Fridericia formula); Other abnormal laboratory test results deemed clinically significant by the investigator.
•3. Positive test results for hepatitis B surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, or Treponema pallidum antibody at screening.
•4. Participants with primary or secondary IgA nephropathy (patients with IgA nephropathy are advised to be screened for the Phase IIa study of the investigational product).
•5. Current diagnosis of tuberculosis (TB); history of active TB with cure \< 5 years prior to screening; or high likelihood of TB infection as judged by the investigator based on comprehensive TB screening during the screening period.
•6. Presence or suspected presence of other active viral, bacterial, fungal, or parasitic infections within 4 weeks before screening.
•7. History of epidemic meningococcal infection, or other recurrent or chronic infections.
•8. History of splenectomy or asplenia.
•9. History of complement abnormalities or hereditary complement deficiency.
+2 more criteria

Key Dates

Start Date

March 15, 2026

Primary Completion Date

December 1, 2026

Completion Date

December 1, 2026

Last Updated

March 3, 2026

Enrollment

ESTIMATED participants

Conditions

Renal ImpairmentsIgA Nephropathy (IgAN)

Interventions

RG002C0106

DRUG

Contacts

Hongwei Tian

CONTACT

8610-63729218 hwtian@rigerna.com

Lingling Zhu

CONTACT

llzhu@rigerna.com

Autoimmune Protocol Diet Intervention on Proteinuria in IgA Nephropathy Patients

NCT07022574

IgA Nephropathy (IgAN)

View study

NOT_YET_RECRUITINGPHASE2

Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)

NCT06687174

IgA Nephropathy (IgAN)

View study

TERMINATEDPHASE2

A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)

NCT03841448

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 3, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.